Publications within peer-reviewed journals
1. Thakore JH, Kelly C, Pritchard JP. Campylobacter Enteritis in a pregnant woman with hypogammaglobulinaemia. Irish Medical Journal 1989;82(4) 165.
2. Bough B, Thakore JH, Davies M, Dowling F. Degeneration of lumbar facet joints: Arthrography and Pathology. Journal of Bone & Joint Surgery (Br) 1990;72-B:275-276.
3. Thakore JH, Dinan TG. Alcohol-free beer and the irreversible monoamine oxidase inhibitors. International Clinical Psychopharmacology 1992;7:59-60.
4. Thakore JH, Dinan TG. Physical dependence following zopiclone usage: A case report. Human Psychopharmacology 1992;7:143-145.
5. Thakore JH, Dinan TG. Serum thyrotropin responses to thyrotropin releasing hormone in Korsakoff's Syndrome. Acta Psychiatrica Scandinavia 1993;8:218-220.
6. Dinan TG, O'Keane V, Thakore JH. Pyridostigmine induced growth hormone responses in mania: focus on the cholinergic / somatostatin system. Clinical Endocrinology 1993;40:93-96.
7. Thakore JH, Dinan TG. Dexamethasone-induced growth hormone release: A dose response study. Human Psychopharmacology 1993;8:285-288.
8. Thakore JH, Dinan TG. Subnormal growth hormone responses to acutely administered dexamethasone in depression. Clinical Endocrinology 1994;40:623-627.
9. Thakore JH, Coffey I, Dinan TG. Time dependency of pyridostigmine-induced growth hormone response. Journal of Basic & Clinical Physiology & Pharmacology 1994;5:1-7.
10. Dinan TG, Thakore JH, O'Keane V. Lowering cortisol enhances growth hormone responses to growth hormone releasing hormone in healthy controls. Acta Physiologica Scandinavia 1994;151:413-416.
11. Thakore JH, Dinan TG. Growth hormone secretion: The role of glucocorticoids. Life Sciences 1994;14:1083-1099.
12. Thakore JH, Dinan TG. D-fenfluramine-induced prolactin release in depression: The acute effects of ketoconazole. Journal of Serotonin Research 1994;1:207-215.
13. Thakore JH, Dinan TG. Effect of fluoxetine on dexamethasone-induced growth hormone responses in depression: a double-blind placebo-controlled study. American Journal of Psychiatry 1995;152:616-618.
14. Thakore JH, Dinan TG. Diurnal variation of growth hormone responses to acutely administered dexamethasone in healthy male volunteers. Hormone & Metabolic Research 1995;27:23-25.
15. Thakore JH, Dinan TG. Growth hormone responses to dexamethasone in healthy females throughout the menstrual cycle. Clinical Endocrinology 1995;42:173-177.
16. Thakore JH, Dinan TG: Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression. Biological Psychiatry 1995;37:364-368.
17. Majeed T, Thakore J, Gray C, Dinan TG Behan PO. Defective dexamethasone-induced growth hormone responses in chronic fatigue syndrome: evidence of glucocorticoid receptor resistance and lack of plasticity? Journal of the Irish College of Physicians & Surgeons 1995;24:20-23.
18. Thakore JH, Dinan TG. Loss of diurnal variation of pyridostigmine-induced growth hormone responses in depression. International Clinical Psychopharmacology 1995;10:107-110.
19. Thakore JH. Hypothalamic-pituitary-adrenal axis overactivity and the pathogenesis of depression. Irish Journal of Psychological Medicine 1996; 13:3-5.
20. Thakore JH, John ND. What advice do FHSAs give GPs about antidepressant prescribing? British Journal of General Practice 1996; 46:363-364.
21. Thakore JH, Dinan TG. Are blunted dexamethasone-induced growth hormone responses specific for depression? Psychological Medicine 1996; 26:1053-1059.
22. Thakore JH, O'Keane V, Dinan TG. d-fenfluramine-induced prolactin responses in mania: evidence of serotonergic subsensitivity. American Journal of Psychiatry 1996; 153:1460-1462.
23. Thakore JH, Berti C, Dinan TG. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatrica Scandinavia 1996; 94:194-197.
24. Thakore JH, Berti C, Dinan TG. Treating depression with specific serotonergic acting drugs. Journal of Serotonin Research 1996; 3:145-160.
25. Thakore JH, Dinan TG. Blunted dexamethasone-induced growth hormone responses in mania. Psychoneuroendocrinology 1996; 21:695-701.
26. Dinan TG, Lavelle E, Cooney J, Burnett F, Scott L, Dash A, Thakore JH, Berti B. Dexamethasone augmentation in treatment resistant depression Acta Psychiatrica Scandinavia 1997; 95:58-61.
27. Maguire TM, Thakore JH, Dinan TG, Hopwood S, Breen KC. Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA axis function. Biological Psychiatry 1997; 41:1131-1136.
28. Thakore, JH, Richards, PJ, Reznek RH, Martin A, Dinan TG. Increased intraabdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biological Psychiatry 1997; 41:1140-1142.
29. Thakore JH. Nefazadone - an effective antidepressant with a dual mode of action. Journal of Serotonin Research 1997; 3:193-202.
30. Thakore, JH, Barnes C, Joyce J, Dinan TG. The effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry Research 1997; 73:27-32.
31. Thakore, JH. Stabilisation of the hypothalamic-pituitary-adrenal axis as a treatment strategy for mood disorders. Human Psychopharmacology 1998; 13:77-81.
32. Berti C, Thakore JH. Cytochrome P450: Its role in psychopharmacology. Journal of Serotonin Research1998; 4:267-271.
33. Thakore JH, Berti C, Dinan TG. Diurnal variation of nicotine-induced ACTH and cortisol secretion in non-smoking healthy male volunteers. Human Psychopharmacology 1999; 14:179-183.
34. Mann JN, Thakore JH. Melancholic depression and abdominal fat distribution: A mini-review. Stress 1999; 3:1-15.
35. Thakore JH, Mann, JN. Effects of dexamethasone augmentation on ACTH/cortisol responses in patients with refractory depression. Journal of Serotonin Research 1999; 5:7-10.
36. Scott LV, Thakore JH, Burnett F, Dinan TG. A preliminary study of dexamethasone treatment on pituitary-adrenal responsivity in major depression. Human Psychopharmacology 1999 19:587-591.
37. Condren RM, Thakore JH. Cushing’s Disease & Melancholia. Stress 2001 4:91-119.
38. Dinan TG, Scott LV, Thakore JH, Naesdel J, Keeling PWN. Impact of cortisol on buspirone stimulated prolactin release: A double-blind placebo-controlled study. Psychoneuroendocrinology 2001 26:751-760.
39. TG Dinan, N Mahmud, O Rathore, J Thakore, E Carr, J Naesdal, CA O’Morain, PWN Keeling. Enhanced central serotinergic responses in nonulcer dyspepsia: a double-blind placebo controlled study of buspirone stimulated prolactin release. Alimentary Pharmacology & Therapeutics 2001 15:1613-1618.
40. Thakore JH, Mann JN, Vlahoos J, Martin A, Reznek R. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002 Jan;26(1):137-41.
41. Ryan MCM, Thakore JH. Physical consequences of schizophrenia. Life Sciences 71: 239-257, 2002.
42. Condren RC, O’Neill A, Ryan MCM, Barrett P, Thakore JH. HPA axis response to a psychological stressor in Social Phobia. Psychoneuroendocrinology 2002 27:693-703.
43. Condren RM, Sharifi N, Thakore JH. A preliminary study of dopamine-mediated prolactin inhibition in generalized social phobia. Psychiatry Research 2002 111:87-92.
44. RC Condren, Dinan TG, Thakore JH. A preliminary study of buspirone stimulated prolactin release in generalized social phobia: evidence for enhanced serotonergic responsivity? Eur Neuropsychopharmacol2002 12:349-54.
45. Walsh M-T, Ryan M, Hillman A, Condren R, Kenny D, Dinan T, Thakore JH. Elevated expression of integrin aIIb bIIIa in drug naive, first episode schizophrenic patients. Biological Psychiatry 2002 52; 874 - 879.
46. Ryan MCM, Collins P, Thakore JH. Impaired Fasting Glucose and Elevation of Cortisol in Drug-Naïve First-Episode Schizophrenia. American Journal of Psychiatry 2003 160; 284-289.
47. Condren RM, Lucey JV, Thakore JH. A preliminary study of baclofen-induced growth hormone release in generalized social phobia. Human Psychopharmacology 2003; 18(2): 125-30.
48. Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH. Atypical antipsychotics and visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004; 74:1999-2008.
49. Thakore JH. Metabolic disturbances in first episode Schizophrenia. British Journal of Psychiatry 2004, 184 (suppl. 47), 03-612.1-5.
50. Ryan MCM, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Pyschoneuroendocrinology 2004; 29:1065-1070.
51. Thakore JH. Metabolic abnormalities in Schizophrenia. British Journal of Psychiatry 2005, 186; 455-456.
52. Breier A, Berg PH, Thakore J, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM. Olanzapine Versus Ziprasidone: Results of the 28-Week Double-Blind Study in Patients With Schizophrenia. American Journal of Psychiatry 2005;162 1879-1887.
53. Walsh P, Spelman L, Sharifi N, Thakore JH. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 2005, 30, 431-437.
54. Dursun S, Dinan TG, Bushe C, Thakore J. Challenges in advancing mental and physical health of patients with serious mental illness. J Psychopharmacol 2005 19: 3-5.
55. Yeap S, Thakore JH. Stress axis dysfunction in schizophrenia. Eur Psychiatry. 2005 Oct;20 Suppl 3:S307-12.
56 . Yeap S, Kelly SP, Sehatpour P, Magno E, Javitt DC, Garavan H, Thakore JH, Foxe JJ Are Early Visual Processing Deficits Endophenotypic for Schizophrenia? A High-Density Electrical Mapping Study in Clinically Unaffected First-Degree Relatives. Arch Gen Psychiatry 2006 Nov;63:1180-1188.
57. Spelman L, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first episode drug naive patients with schizophrenia. Diabet Med. 2007 Mar 22;24(5):481-5.
58. Ni Mhaolain AM, Thakore JH. Interferon-alpha induced mania during the adjuvant treatment of malignant melanoma. Ir J Med Sci. 2007 Mar 30; 176(2):137-9.
59. Yeap S, Kelly SP, Sehatpour P, Magno E, Garavan H, Thakore JH, Foxe JJ. Visual sensory processing deficits in Schizophrenia and their relationship to disease state. Eur Arch Psychiatry Clin Neurosci. 2008 May 26. 258(5):305-16.
60. Yeap S, Kelly SP, Thakore JH, Foxe JJ. Visual sensory processing deficits in first-episode patients with Schizophrenia. Schizophr Res. 2008 May 14; 102(1-3):340-3.
61. Magno E, Yeap S, Thakore JH, Garavan H, De Sanctis P, Foxe JJ. Are Auditory-Evoked Frequency and Duration Mismatch Negativity Deficits Endophenotypic for Schizophrenia? High-Density Electrical Mapping in Clinically Unaffected First-Degree Relatives and First-Episode and Chronic Schizophrenia. Biol Psychiatry. 2008 May 8. 1;64(5):385-91.
62. Yeap S, Kelly SP, Reilly RB, Thakore JH, Foxe JJ. Visual sensory processing deficits in patients with bipolar disorder revealed through high-density electrical mapping. J Psychiatry Neurosci 2009;34(6):459-64.
63. Rapcan V, D’Arcy S, Yeap S, Afzal N, Thakore JH, Reilly R. Acoustic and Temporal Analysis of Speech: A Potential Biomarker for Schizophrenia. Med Eng Phys. 2010 Nov;32(9):1074-9.
64. Foxe JJ, Yeap S, Snyder AC, Kelly SP, Thakore JH, Molholm S.The N1 auditory evoked potential component as an endophenotype for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives, first-episode, and chronic schizophrenia patients. Eur Arch Psychiatry Clin Neurosci. 2011 Aug;261(5):331-9.
65. O’Connell K, Thakore JH, Dev KK. Investigating levels of S100B in patients with schizophrenia. BMC Psychiatry.2013, 13:146.
66. O'Connell KE, Thakore J, Dev KK. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophr Res. 2014 Jun;156(1):1-8.
67. O'Connell KE, Thakore J, Dev KK. Increased interleukin 23 (IL23) levels in schizophrenia patients treated with depot antipsychotic medication. Cytokine. 2015 May;73(1):196-8.